Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 4/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17009690 | 0.87 | PTGER4 (0.55) | PTGER4IDH1KDM4ENPC1RAB9A | |
| SCHEMBL28306195 | 0.86 | ALDH1A1 (0.42) | PTGER4IDH1KDM4ENPC1CASP3 | |
| SCHEMBL17009890 | 0.77 | PTGER4 (0.42) | PTGER4IDH1PTPN1KDM4ENPC1 | |
| SCHEMBL17009810 | 0.77 | PTGER4 (0.42) | PTGER4IDH1KDM4ENPC1CASP3 | |
| SCHEMBL17009991 | 0.74 | ALOX15 (0.39) | PTPN1KDM4ENPC1HSD17B10PTPN2 | |
| SCHEMBL17010418 | 0.74 | PTGER4 (0.52) | PTGER4IDH1KDM4ETDP1 | |
| SCHEMBL17010419 | 0.74 | PTGER4 (0.52) | PTGER4IDH1KDM4ETDP1 | |
| SCHEMBL17010421 | 0.74 | PTGER4 (0.52) | PTGER4IDH1KDM4ETDP1 | |
| SCHEMBL20685310 | 0.73 | PTGER4 (0.54) | PTGER4IDH1KDM4EHSD17B10ALOX15 | |
| SCHEMBL555823 | 0.72 | KDM4E (0.48) | PTPN1KDM4ENPC1CASP3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3209660-B1 | 1-CYCLOHEXYL-2-PHENYLAMINOBENZIMIDAZOLES AS MIDH1 INHIBITORS FOR THE TREATMENT OF TUMORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2020-06-17 | — | — | EP | disclosed |
| EP-3105210-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2019-01-30 | — | — | EP | disclosed |
| US-10137110-B2 | 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-27 | — | — | US | disclosed |
| US-9951027-B2 | Benzimidazol-2-amines as MIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-20170319549-A1 | 1-CYCLOHEXYL-2-PHENYLAMINOBENZIMIDAZOLES AS MIDH1 INHIBITORS FOR THE TREATMENT OF TUMORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-09 | — | — | US | disclosed |
| EP-3209660-A1 | 1-CYCLOHEXYL-2-PHENYLAMINOBENZIMIDAZOLES AS MIDH1 INHIBITORS FOR THE TREATMENT OF TUMORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-08-30 | — | — | EP | disclosed |
| US-20170197922-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2017-07-13 | — | — | US | disclosed |
| EP-3105210-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015121209-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319549-A1 | 1-CYCLOHEXYL-2-PHENYLAMINOBENZIMIDAZOLES AS MIDH1 INHIBITORS FOR THE TREATMENT OF TUMORS | HRH1, MDN1, MDH1 | PTGER4 3666/4885IDH1 58/4885PTPN1 3079/4885 |
| US-10137110-B2 | 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors | HRH1, MDN1, MDH1 | PTGER4 3666/4885IDH1 58/4885PTPN1 3079/4885 |
| US-20170197922-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | HRH1, HRH2, HRH3 | PTGER4 4012/4885IDH1 166/4885PTPN1 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.